Tag: major depressive disorder industry insights

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Major Depressive Disorder Market Expected to Grow Between 2025 And 2029?

There has been a stable expansion in the market size for major depressive disorder over the recent years. An increase from $6.12 billion in 2024 to $6.26 billion in 2025 is expected, with a compound annual growth rate (CAGR) of 2.3%. This increase during the historic phase can be credited to advancements in pharmaceuticals, awareness about mental health, psychological therapies, and initiatives in public health.

The major depressive disorder market size is expected to see steady growth in the next few years. It will grow to $7.14 billion in 2029 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to precision medicine, telepsychiatry and teletherapy, novel treatment modalities, global expansion of mental health services. Major trends in the forecast period include early intervention, peer support and online communities, holistic approaches, resilience and coping strategies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

Which Primay Drivers Are Accelerating Growth in the Major Depressive Disorder Market?

The escalation in instances of substance misuse and alcohol addiction is anticipated to drive the expansion of the major depressive disorder market. Substance and alcohol addiction reference harmful and excessive usage patterns of various substances, including alcohol, leading to detrimental physical, psychological and social results. Major depressive disorder often occurs alongside this, and the coexistence of the two can cause a significant escalation in the risk of physical and mental damage. For example, a survey issued in July 2024 by the Substance Abuse and Mental Health Services Administration, a department of health and human services in the US, revealed that 3.1% of individuals (equivalent to 8.9 million) abused opioids in 2023. Moreover, 21.8% of people 12 years or older used marijuana, making it the most frequently misused illegal drug. Furthermore, in the previous month, 9.4% of those aged 12 or older had used nicotine vapes, rising from 8.3% in 2022. Hence, the escalation in the frequency of substance misuse and alcohol addiction is fueling the expansion of the major depressive disorder market.

Which Primary Segments of the Major Depressive Disorder Market Are Driving Growth and Industry Transformations?

The major depressive disordermarket covered in this report is segmented –

1) By Treatment: Psychotherapy; Medications; Electroconvulsive Therapy (ECT); Transcranial Magnetic Stimulation (TMS); Other Treatments

2) By Diagnosis: Physical Examinations; Laboratory Tests; Psychiatric Evaluations; Diagnostic And Statistical Manual of Mental Disorders (DSM-5); Other Diagnosis

3) By End-User: Clinics; Hospitals; Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT); Interpersonal Therapy (IPT); Dialectical Behavior Therapy (DBT); Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs); Tricyclic Antidepressants (TCAs); Monoamine Oxidase Inhibitors (MAOIs); Atypical Antidepressants

3) Electroconvulsive Therapy (ECT): Unilateral ECT; Bilateral ECT; Modified ECT

4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS); Deep Transcranial Magnetic Stimulation (dTMS); Theta Burst Stimulation (TBS); Navigated Brain Stimulation (nTMS)

5) Other: Cognitive Behavioral Therapy (CBT); Psychodynamic Therapy; Interpersonal Therapy (IPT); Vagus Nerve Stimulation (VNS); Ketamine Therapy; Bright Light Therapy; Psychedelic-Assisted Therapy; Medication (Antidepressants)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13042&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Major Depressive Disorder Market?# Market?

North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which Technological Trends Are Reshaping the Major Depressive Disorder Industry Dynamics?

The focus of leading firms in the major depressive disorder market is to gain an edge over competitors by creating and receiving approval for innovative products. As the demand for safer and more effective treatments rises, there has been an increase in drug approvals for the treatment of major depressive disorders, including VRAYLAR (cariprazine). In December 2022, the US-based pharmaceutical company, AbbVie Inc., obtained approval from the Food and Drug Administration (FDA) to use VRAYLAR (cariprazine) as a supplemental therapy to antidepressants for adults suffering from major depressive disorder (MDD). Designed as an unconventional antipsychotic medication, VRAYLAR, which adjusts dopamine and serotonin concentrations in the brain, became the first of its kind approved for additional treatment for major depressive disorder. Moreover, VRAYLAR comes in a capsule that is taken once a day.

View the full report here:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

What Parameters Are Used to Define the Major Depressive Disorder Market?

Major depressive disorder refers to a mood disorder or depression that causes a persistent feeling of sadness and loss of interest, which can interfere with daily activities such as sleeping, eating, or working. It goes beyond normal fluctuations in mood and can significantly impact a person’s thoughts, feelings, behavior and physical well-being. The treatment for major depressive disorder involves several medical interventions that support the emotional well-being of an individual.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13042

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the major depressive disorder industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Major Depressive Disorder Market Growth Evolved From 2024 To 2025, And What’s Ahead?

Over the years, the market size for major depressive disorder has experienced a consistent growth. It is set to expand from a value of $6.12 billion in 2024 to reach $6.28 billion by 2025, showcasing a compound annual growth rate (CAGR) of 2.6%. The significant rise during the historical period is the result of advancements in pharmaceuticals, heightened mental health consciousness, the provision of psychological therapies, and diverse public health campaigns.

In the coming years, the market size for major depressive disorder is projected to experience consistent growth, ultimately reaching $7.13 billion in 2029 with a compound annual growth rate (CAGR) of 3.2%. This predicted growth during the forecast period can be credited to the advancements in precision medicine, the emergence of telepsychiatry and teletherapy, new treatment methods, as well as the worldwide expansion of mental health services. Key trends during the forecast period likely to influence the market are early intervention, peer assistance and online gatherings, holistic methodologies, and resilience and coping tactics.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

What External and Internal Drivers Are Contributing to the Growth of the Major Depressive Disorder Market?

The increasing prevalence of substance and alcohol misuse is expected to boost the development of the major depressive disorder market. Substance and alcohol misuse is marked by hazardous overconsumption of substances, including alcohol, leading to adverse physical, psychological, and societal impacts. This behavior often coincides with major depressive disorder, with both conditions escalating one’s risk of mental and physical harms. In a 2024 report by the Substance Abuse and Mental Health Services Administration, a US health and human services department, data showed that 3.1% of the population (8.9 million people) abused opioids in 2023, while 21.8% of individuals over 12 consumed marijuana, the most commonly misused drug. Furthermore, there was an increase in nicotine vaping among those 12 or older from 8.3% in 2022 to 9.4% in 2024. Consequently, these increasing levels of substance and alcohol misuse are fueling the expansion of the major depressive disorder market. In another driver, the rise in anxiety cases is also expected to contribute to the growth of the major depressive disorder market. Anxiety, a normal reaction to stress, elicits feelings of fear, apprehension, and discomfort. This temporary state of severe and constant worry about everyday situations has a significant effect on major depressive disorders, leading to nervousness, irritability, and issues with sleep and concentration. Evidence from the American Psychiatric Association, a non-profit organization based in the US, indicated that in 2024, 43% of adults reported more anxiety than the previous year, an increase from 37% in 2023 and 32% in 2022. This rise in anxiety cases is thus propelling the growth of the major depressive disorder market.

What Segment Types Define the Major Depressive Disorder Market Structure?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5), Other Diagnosis

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) Other: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13042&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Major Depressive Disorder Market?

North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Major Depressive Disorder Market?

Leading enterprises in the major depressive disorder market are concentrating on creating innovative products and securing their approval to gain a competitive edge. The approval rate of drugs for treating major depressive disorder, such as VRAYLAR (cariprazine), is on a rise due to the increasing need for safer and more effective treatment options. For example, in December 2022, the US-based pharmaceutical company AbbVie Inc., received an approval for VRAYLAR (cariprazine) as a supplemental treatment to antidepressants for adult patients of major depressive disorder (MDD), granted by Food and Drug Administration (FDA), a U.S. federal agency. VRAYLAR, an innovative atypical antipsychotic medication, helps in maintaining a balance between dopamine and serotonin levels in the brain. It’s the first of its kind to be approved as a supplemental treatment for major depressive disorder. Additionally, it comes in the form of a capsule and is taken once a day.

View the full report here:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

What Is the Definition of the Major Depressive Disorder Market?

Major depressive disorder refers to a mood disorder or depression that causes a persistent feeling of sadness and loss of interest, which can interfere with daily activities such as sleeping, eating, or working. It goes beyond normal fluctuations in mood and can significantly impact a person’s thoughts, feelings, behavior and physical well-being. The treatment for major depressive disorder involves several medical interventions that support the emotional well-being of an individual.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13042

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theMajor Depressive Disorder Market?

The surge in instances of substance and alcohol misuse is anticipated to boost the expansion of the major depressive disorder industry. These terms refer to the overuse or harmful use of things like alcohol, which results in detrimental physical, psychological, and societal repercussions. The likelihood of major depressive disorder is commonly heightened with substance or alcohol abuse, with both often exacerbating the impacts of the other, thereby elevating the risk of harm, both mentally and physically. As an example, statistics released in July 2024 from the Substance Abuse and Mental Health Services Administration, a department of health and human services in the US, stated that 3.1% of individuals, or 8.9 million people, misused opioids in 2023, and 21.8% of individuals 12 or older used marijuana, the most frequently used illegal drug. Furthermore, it was noted that 9.4% of people 12 or older had recently vaped nicotine, an increase from the 8.3% in 2022. As a result of these escalating rates of substance and alcohol abuse, the major depressive disorder industry is growing. The major depressive disorder market is also being fuelled by the escalating number of anxiety cases. Anxiety, characterised by fear, dread, and uneasiness, is a common reaction to stress, often resulting in excessive concern about everyday events. Because anxiety can lead to nervousness, irritability, and issues with sleep and concentration, it significantly contributes to major depressive disorder. Furthermore, figures from the American Psychiatric Association, a not-for-profit organization in the US, revealed in May 2024 that 43% of adults confessed to experiencing increased anxiety compared to the previous year, an uptick from 37% in 2023 and 32% in 2022. Therefore, the increasing occurrences of anxiety are driving the expansion of the major depressive disorder market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

#How Does the ProjectedMajor Depressive Disorder Market Growth Compare Over the Forecast Period?

The market size for major depressive disorder has been gradually increasing over the recent years. The market is projected to expand from $6.12 billion in 2024 to $6.28 billion in 2025, with a compound annual growth rate (CAGR) of 2.6%. The growth observed during the historical period can be linked to advancements in pharmaceuticals, increased consciousness about mental health, psychological treatments, and public health campaigns.

Anticipated steady growth is predictable for the major depressive disorder market in the coming years. The market size is projected to expand to the value of $7.13 billion by 2029, with a compound annual growth rate (CAGR) of 3.2%. This expected growth during the forecast period is primarily influenced by factors such as precision medicine, telepsychiatry and teletherapy, innovative treatment models, and the worldwide expansion of mental health services. Essential trends for the forecast period encompass early intervention, peer support augmented by online communities, comprehensive methodologies, resilience, and coping mechanisms.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13042

Which Upcoming Market Trends and Innovations Are Set to Influence theMajor Depressive Disorder Market’s Path Forward?

Leading companies in the machinery and industrial automation market are starting to concentrate more on the production of industrial automation products to raise their profitability margin. These products encompass a variety of technological advancements and apparatus built to streamline and enhance industrial operations. For instance, Renishaw Inc., a company from the UK that operates in the machine industry, introduced a fresh line of industrial automation products in May 2023. This product line comprises three distinct items, namely RCS L-90, RCS T-90, and RCS P-series, all complemented by a customized software suite. The recently launched RCS product line seeks to tackle prevalent issues in the global industrial automation sector, specifically focusing on manual setup, robot calibration, and maintenance. The RCS L-90 is a ball-bar device that boosts the precision of the robot system, decreases setup time, and keeps a check on the health of the robot. Similarly, RCS T-90 is a tri-ball bar system that empowers users to detect the underlying reasons for subpar performance and gather crucial information about the robot.

Who Are the Dominant Market Players Pushing the Boundaries of theMajor Depressive Disorder Market?

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

What Are the Core Segments of the Major Depressive Disorder Market, and How Do They Contribute to Growth?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5), Other Diagnosis

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) Other: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13042&type=smp

What Regions Are Dominating the Major Depressive Disorder Market Growth?

North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Major Depressive Disorder Market 2025, By The Business Research Company:

Residential Substance Abuse And Mental Health Facilities Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/residential-substance-abuse-and-mental-health-facilities-global-market-report

Mental Health Apps Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/mental-health-apps-global-market-report

Telepsychiatry Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/telepsychiatry-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Analyzing the Growth Rate of the Major Depressive Disorder Market: What’s the Expected CAGR for the Next Decade?

The market for major depressive disorder has seen a consistent increase in size over recent time. It is projected to rise from $6.12 billion in 2024 to $6.28 billion in 2025, indicating a compound annual growth rate (CAGR) of 2.6%. This growth during the historic period can be contributed to the advancements in pharmaceuticals, increased mental health consciousness, psychological treatments, and public health programs.

In the coming years, we anticipate stable expansion in the market size for major depressive disorder. It’s projected to escalate to $7.13 billion by 2029, with a compound annual growth rate (CAGR) of 3.2%. Factors contributing to the growth throughout the forecast duration include advancements in precision medicine, telepsychiatry and teletherapy, innovative treatment methods, and the worldwide spread of mental health services. Significant trends expected within this period encompass early intervention, peer backing and digital communities, integrated approaches, as well as tactics for resilience and coping.

Which Macro and Microeconomic Factors Are Accelerating the Growth of the major depressive disorder Market?

The major depressive disorder market is predicted to expand due to an increase in substance abuse and alcoholism cases. Substance and alcohol misuse refer to harmful and excessive usage patterns that can result in undesirable physical, psychological, and social outcomes. Substance and alcohol misuse often coincide with major depressive disorder, exacerbating the risk of bodily and mental harm. For example, a study in July 2024 by the Substance Abuse and Mental Health Services Administration (a division of US Health and Human Services) revealed that 3.1% of people (about 8.9 million) misused opioids in 2023, and 21.8% of individuals aged 12 or above consumed marijuana, the most commonly used illegal drug. Furthermore, 9.4% of individuals aged 12 or more vaped nicotine in the previous month, a growth from 8.3% in 2022. Hence, the increasing instances of substance and alcohol misuse are contributing to the expansion of the major depressive disorder market.

Major Depressive Disorder Market Driver: Rise in Anxiety Cases Fuels Market Expansion

 

Request Your Free Major Depressive Disorder Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

What Are the Leading Organizations Impacting the Major Depressive Disorder Market’s Growth?

Major companies operating in the major depressive disorder market are:

• Pfizer Inc._x000D_

• Janssen Research And Development LLC_x000D_

• Merck and Co. Inc._x000D_

• Novartis AG_x000D_

• Sanofi-Aventis US LLC_x000D_

What Are the Most Prominent Trends Driving Change in the Major Depressive Disorder Market?

Key businesses in the major depressive disorder industry are concentrated on creating novel products and obtaining necessary approvals to establish a competitive edge. The number of approved drugs for treating major depressive disorder, such as VRAYLAR (cariprazine), is on the rise due to demand for safer and more effective therapies. For example, in December 2022, the US-based pharmaceutical corporation, AbbVie Inc., secured approval from the US federal agency, the Food and Drug Administration (FDA), for VRAYLAR (cariprazine) to serve as a supplementary therapy to antidepressants for adults with major depressive disorder (MDD). VRAYLAR is a groundbreaking atypical antipsychotic medication that regulates dopamine and serotonin levels in the brain and stands as the first atypical antipsychotic authorized as a supplementary treatment for major depressive disorder. Moreover, it comes in the form of a capsule and is ingested once daily.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

Which Key Segments of the Major Depressive Disorder Market Are Poised for Growth and Innovation?

The major depressive disorder market covered in this report is segmented –

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments

2) By Diagnosis: Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5), Other Diagnosis

3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:

1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy

2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants

3) Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT

4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)

5) Other: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

What Regions Are Leading the Charge in the Major Depressive Disorder Market?

North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

How Is the Major Depressive Disorder Market Categorized and Defined in the Industry?

Major depressive disorder refers to a mood disorder or depression that causes a persistent feeling of sadness and loss of interest, which can interfere with daily activities such as sleeping, eating, or working. It goes beyond normal fluctuations in mood and can significantly impact a person’s thoughts, feelings, behavior and physical well-being. The treatment for major depressive disorder involves several medical interventions that support the emotional well-being of an individual.

Browse Through More Similar Reports By The Business Research Company:

Residential Substance Abuse And Mental Health Facilities Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/residential-substance-abuse-and-mental-health-facilities-global-market-report

Mental Health Apps Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/mental-health-apps-global-market-report

Telepsychiatry Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/telepsychiatry-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: